GlassScriptPhysician profile
James V Allen
NPI 1548266554
$3,286.55
in general payments reported to CMS, 2019-2025
30 companies · $370 in 2025
The $370 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $469 · 2020: $302 · 2021: $116 · 2022: $217 · 2023: $710 · 2024: $1,102 · 2025: $370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,182.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $509.97 | 2019-2025 | Skyrizi, Rinvoq |
| Amgen INC. | $360.17 | 2019-2025 | Otezla, Otezla |
| Genzyme Corporation | $294.30 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $269.78 | 2019-2025 | Dupixent, Libtayo |
| Pfizer INC. | $226.91 | 2023-2025 | |
| Lilly USA, LLC | $216.33 | 2019-2024 | Taltz, Zepbound, Olumiant |
| Dermavant Sciences, INC. | $188.79 | 2023-2024 | Vtama |
| Janssen Biotech, INC. | $169.55 | 2020-2024 | Tremfya |
| Incyte Corporation | $124.31 | 2023-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $122.20 | 2019-2025 | Ilumya |
| Galderma Laboratories, L.P. | $99.21 | 2019-2025 | Nemluvio |
| Ucb, INC. | $90.35 | 2019-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $83.20 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $72.90 | 2024 | Sotyktu |
| Organon LLC | $53.94 | 2025 | Vtama |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $42.36 | 2024 | Tremfya |
| Leo Pharma INC. | $41.39 | 2024-2025 | Adbry |
| Almirall LLC | $39.13 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $34.95 | 2019 | |
| Genentech USA, INC. | $34.91 | 2019-2023 | Xolair |
| Kerecis Limited | $34.01 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $30.53 | 2019-2025 | Cabtreo |
| Mayne Pharma Commercial LLC | $28.00 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.65 | 2025 | Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.76 | 2023 | Trulance |
| Dusa Pharmaceuticals, INC. | $18.65 | 2019 | |
| Celgene Corporation | $16.77 | 2019 | |
| Arcutis Biotherapeutics, INC. | $15.23 | 2024 | Zoryve |
| Epi Health, LLC | $11.76 | 2019 | |
| Prugen, INC. Pharmaceuticals | $6.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.